These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26378996)

  • 1. Evaluation of the quality of life in subjects with a history of severe anaphylactic reaction to the Hymenoptera venom.
    Nowak N; Bazan-Socha S; Pulka G; Pełka K; Latra P
    Pneumonol Alergol Pol; 2015; 83(5):352-8. PubMed ID: 26378996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Influence of venom immunotherapy on anxiety level of being re-stung].
    Sacha M; Czarnobilska E; Stobiecki M; Dyga W
    Przegl Lek; 2012; 69(12):1261-5. PubMed ID: 23750435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Follow-Up of Children after Venom Immunotherapy: Low Adherence to Anaphylaxis Guidelines.
    Fiedler C; Miehe U; Treudler R; Kiess W; Prenzel F
    Int Arch Allergy Immunol; 2017; 172(3):167-172. PubMed ID: 28380475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of venom immunotherapy on serum level of CCL5/RANTES in patients with Hymenoptera venom allergy.
    Gawlik R; Glück J; Jawor B; Rogala B
    Immunopharmacol Immunotoxicol; 2015; 37(4):375-9. PubMed ID: 26181651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
    Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM
    J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Vespid Allergy Quality of Life Questionnaire - cultural adaptation and translation to Portuguese.
    Silva D; Pereira AM; Santos N; Amaral L; Delgado L; Oude Elberink JN; Coimbra A
    Eur Ann Allergy Clin Immunol; 2017 May; 49(3):114-121. PubMed ID: 28497674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy.
    von Moos S; Graf N; Johansen P; Müllner G; Kündig TM; Senti G
    Int Arch Allergy Immunol; 2013; 160(1):86-92. PubMed ID: 22948338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
    Spoerl D; Bircher AJ; Scherer K
    J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hymenoptera venom allergy.
    Przybilla B; Ruëff F
    J Dtsch Dermatol Ges; 2010 Feb; 8(2):114-27; quiz 128-30. PubMed ID: 19751222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
    Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
    Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom.
    Oude Elberink JN; De Monchy JG; Van Der Heide S; Guyatt GH; Dubois AE
    J Allergy Clin Immunol; 2002 Jul; 110(1):174-82. PubMed ID: 12110838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic and local reactions of bee venom immunotherapy in Iran.
    Bemanian MH; Farhoudi A; Pourpak Z; Gharagozlou M; Movahedi M; Nabavi M; Mozafari H; Mohammadzadeh I; Chavoshzadeh Z; Shirkhoda Z
    Iran J Allergy Asthma Immunol; 2007 Dec; 6(4):203-6. PubMed ID: 18094443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-dependent sting recurrence and outcome in immunotherapy-treated children with anaphylaxis to Hymenoptera venom.
    Stritzke AI; Eng PA
    Clin Exp Allergy; 2013 Aug; 43(8):950-5. PubMed ID: 23889248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in children and adolescents after systemic sting reaction.
    Brzyski P; Cichocka-Jarosz E; Tarczoń I; Jedynak-Wąsowicz U; Tomasik T; Lis G
    Ann Agric Environ Med; 2019 Mar; 26(1):103-108. PubMed ID: 30922038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
    Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
    Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis.
    Bernstein JA; Kagen SL; Bernstein DI; Bernstein IL
    Ann Allergy; 1994 Nov; 73(5):423-8. PubMed ID: 7978535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunotherapy against hymenoptera venom: report of ten patients].
    Guzmán M MA; Salinas L J; Toche P P; Marinovic M MA; Gallardo O AM
    Rev Med Chil; 2007 Dec; 135(12):1566-71. PubMed ID: 18357358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hyper-accelerated immunotherapy with Hymenoptera venoms].
    Sabbah A; Bonneau JC; Drouet M; Le Sellin J
    Allerg Immunol (Paris); 1987 Apr; 19(4):156-8, 160, 162-3. PubMed ID: 3453132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro basophil activation using CD63 expression in patients with bee and wasp venom allergy.
    Eberlein-König B; Schmidt-Leidescher C; Rakoski J; Behrendt H; Ring J
    J Investig Allergol Clin Immunol; 2006; 16(1):5-10. PubMed ID: 16599242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.